RAPT Therapeutics's 15min chart triggered KDJ Golden Cross, bullish Marubozu candlestick pattern.

RAPT Therapeutics's 15-minute chart has recently exhibited a significant bullish trend, as indicated by the KDJ Golden Cross and Bullish Marubozu patterns observed on August 12, 2025 at 13:30. This shift in momentum suggests that the stock's price is poised to continue its upward trajectory, with increased buying pressure dominating the market. As a result, investors can anticipate a continuation of the bullish trend, with potential for further gains in the coming days.

July 2, 2025

On August 12, 2025, at 13:30, RAPT Therapeutics Inc (RAPT) exhibited a significant shift in its stock price momentum, as indicated by the appearance of a KDJ Golden Cross and a Bullish Marubozu on its 15-minute chart. This bullish trend suggests a potential upward trajectory for the stock, with buyers maintaining control of the market [1].

The KDJ Golden Cross is a technical indicator that signals a shift in momentum from bearish to bullish. When the KDJ line crosses above the signal line, it suggests that the stock price is likely to increase. The Bullish Marubozu pattern, characterized by a long white candle with no shadows, further supports this bullish momentum by indicating strong buying pressure [2].

The presence of these indicators suggests that RAPT Therapeutics may experience further price increases. The stock has already seen a notable rise, gaining 24.9% this quarter and losing 21.0% year-to-date. However, the company reported a quarterly adjusted loss of 65 cents per share, which was higher than the same quarter last year. Despite this, the stock has shown resilience and potential for growth [3].

Investors should closely monitor RAPT Therapeutics' performance and consider these technical indicators in conjunction with the company's fundamental financial health. The company's earnings report for the quarter ended June 30, 2025, showed a loss of 65 cents per share, which was higher than the mean expectation of 64 cents per share. However, the company's revenue was zero, aligning with analyst expectations [3].

Clear Street has raised its price target on Rapt Therapeutics (NASDAQ:RAPT) to $24.00 from $3.00 while maintaining a Buy rating, citing the potential of the company’s RPT904 antibody. According to InvestingPro data, analyst targets for RAPT range from $8 to $48, with the stock currently trading at $9.99, suggesting significant upside potential. The stock has shown strong momentum, gaining over 7% in the past six months despite broader market volatility [2].

The firm points to forthcoming second-half 2025 data that will directly compare RPT904—described as a potentially best-in-class anti-IgE antibody—with XOLAIR as a major catalyst for Rapt’s valuation. RPT904 is advancing for food allergy treatment with Phase 2b trials starting in the second half of 2025, while data from Rapt’s Chinese partner Jemincare on chronic spontaneous urticaria (CSU) and asthma applications is imminent. InvestingPro analysis reveals the company maintains a strong financial health score, particularly in cash flow management, which is crucial for supporting its ongoing clinical trials [2].

In summary, RAPT Therapeutics Inc's 15-minute chart indicates a bullish trend, with strong buying pressure and potential for further price increases. Investors should keep an eye on the stock's performance and consider the company's financial health and broader market conditions.

References:
[1] https://www.ainvest.com/news/rapt-therapeutics-sees-kdj-golden-cross-bullish-marubozu-15min-chart-2508-13/
[2] https://za.investing.com/news/analyst-ratings/clear-street-raises-rapt-therapeutics-stock-price-target-to-24-on-rpt904-potential-93CH-3825042
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2OQ:0-rapt-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/